Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:13:59 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CHRS - COHERUS BIOSCIENCES INC - http://www.coherus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CHRS - Q0.61.95·2.070.52.04+0.115.7907.21,6722,9351.94  2.06  1.938.22  1.430119:09:38Apr 2415 min RT 2¢

Recent Trades - Last 10 of 2935
Time ETExPriceChangeVolume
19:09:38Q2.01180.08181
16:20:01Q2.040.11824
16:19:47Q2.010.081,000
16:13:43Q2.040.1138
16:13:07Q2.010.081
16:02:03Q2.040.112,500
16:02:01Q2.040.11233
16:00:08Q2.040.11300
16:00:06Q2.040.11824
16:00:02Q2.040.1113

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 10:02U:CHRSNews ReleaseCoherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024-04-08 08:30U:CHRSNews ReleaseCoherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
2024-03-13 16:01U:CHRSNews ReleaseCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
2024-03-05 16:01U:CHRSNews ReleaseCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
2024-03-04 01:00U:CHRSNews ReleaseCoherus Completes Divestiture of Ophthalmology Franchise
2024-02-23 17:33U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2024-02-21 08:30U:CHRSNews ReleaseCoherus Announces U.S. Launch of UDENYCA ONBODY ¢ „ ¢ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2024-02-05 08:00U:CHRSNews ReleaseCoherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2024-01-22 01:15U:CHRSNews ReleaseCoherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-18 16:05U:CHRSNews ReleaseCoherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
2024-01-04 08:00U:CHRSNews ReleaseINOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI ¢ „ ¢ (toripalimab-tpzi)
2024-01-03 09:00U:CHRSNews ReleaseCoherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:29U:CHRSNews ReleaseCoherus Announces U.S. Launch of LOQTORZI ¢ „ ¢
2023-12-26 16:01U:CHRSNews ReleaseCoherus Announces FDA Approval of UDENYCA ONBODY ¢ „ ¢, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2023-12-22 17:00U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-12-11 08:30U:CHRSNews ReleaseCoherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
2023-12-07 17:56U:CHRSNews ReleaseCoherus BioSciences Announces CFO Transition Plans
2023-12-06 04:00U:CHRSNews ReleaseCoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
2023-11-28 11:16U:CHRSNews ReleaseCoherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical As
2023-11-06 16:08U:CHRSNews ReleaseCoherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights